Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.
about
Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus.Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells.Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding.AS03- and MF59-Adjuvanted Influenza Vaccines in Children.Granulocytes: New Members of the Antigen-Presenting Cell Family.Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response.T Cell Subsets in the Germinal Center: Lessons from the Macaque Model.Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity.TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25.Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in MacaquesHarnessing T Follicular Helper Cell Responses for HIV Vaccine DevelopmentNeutrophil Vaccination Dynamics and Their Capacity To Mediate B Cell Help in Rhesus MacaquesOptimizing the utilization of aluminum adjuvants in vaccines: you might just get what you wantClass-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4 T Cell-Independent CD8 T-Cell Response Against Unconjugated Protein AntigenUnraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action
P2860
Q41993335-DC92FADC-8027-469B-BB99-09378C7DF82DQ45325639-E53807B0-174C-490B-AE88-0ED3F0715AF2Q47112853-9B89C9CA-F2D9-43DF-93A6-126684A57F50Q47242905-A21AC558-39DF-467D-84DC-DD5E54F2D070Q47658890-D9C2A772-01BC-47FA-B469-EE74FD79B9C7Q49530934-91A7C822-7F8D-4417-A283-650815D24951Q49958499-DBF99F08-F794-4A84-A8C3-03DB3055BD32Q52657148-6738D392-7495-4A27-B95D-76D11ED745BEQ55005132-FBB9A2E7-F630-4C10-913F-B36EDE7B4B11Q55379719-ABD513FE-4C2A-41A0-A688-BEE27D83E3E1Q56517308-6751C57F-A529-45C1-A2F0-6095AF66BB75Q56950294-85F600A4-BABA-4BA5-9112-CF4B5E49F9AEQ57464684-42E7E043-17D8-4796-A300-4A49EBE064A8Q57478910-45F13D41-3104-404C-90B3-FE4B6C21B028Q58575827-5EB88DD0-2556-4CEC-892D-70A65754BF2DQ59137099-2C7AAC85-0D3F-4E7E-B234-59894884B1CD
P2860
Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Vaccine priming is restricted ...... uvant-mediated antigen uptake.
@en
type
label
Vaccine priming is restricted ...... uvant-mediated antigen uptake.
@en
prefLabel
Vaccine priming is restricted ...... uvant-mediated antigen uptake.
@en
P2093
P2860
P50
P1476
Vaccine priming is restricted ...... juvant-mediated antigen uptake
@en
P2093
Derek T O'Hagan
Elizabeth A Thompson
Ennio De Gregorio
Joseph R Francica
Kerrie J Sandgren
Nancy J Sullivan
Richard A Koup
Robert A Seder
Susan Barnett
P2860
P356
10.1126/SCITRANSLMED.AAL2094
P407
P577
2017-06-01T00:00:00Z